Close this search box.

IGCPharma revolutionizing

Alzheimer's Care

Cannabinoid-based drugs have the potential to improve the lives of millions with Alzheimer’s disease

Alleviating the Debilitating Symptoms
of Alzheimer’s

Our drug candidate, IGC-AD1, has shown promising results in treating agitation in Alzheimer’s patients. 

IGC Pharma
IGC Pharma

What we do is Important

With no known cure, our formulations have the potential to change lives


Americans with
disease in 2022


Americans with
Alzheimer’s disease
by 2060

5th Leading

Cause of death among
Americans age 65+

$ 0

Expected cost of Alzheimer’s and dementia by 2050 if no treatment or cure is found

Click Here
Click Here
Click Here
Click Here
Click Here
Click Here

What We Do
is Unique

Scroll Down

60-70% of Alzheimer’s patients suffer from debilitating symptoms, such as agitation, anxiety, and depression.


There are no FDA-approved
drugs to treat agitation in Alzheimer’s.


Agitation is emotional distress,
verbal and physical aggression.
It is associated with higher admissions to assisted living
facilities, long-term
and higher mortality.


IGC-AD1 Phase 1 studies
showed promise to treat
agitation in Alzheimer’s.


IGC-AD1 is the FIRST natural cannabis-based
patent-protected compound
that relies on low doses
of THC and another compound
as active pharmaceutical ingredients (API) for the
treatment of agitation in Alzheimer’s.


The ONLY natural THC-based investigational drug candidate currently undergoing FDA trials registered on

Major milestones

IGC Pharma


Development of cannabis-based formulations for neurological disorders such as Alzheimer’s disease, Epilepsy, and Tourette Syndrome.

IGC Pharma


Filed patents on the use of cannabinoids for pain, seizures, and eating disorders.  

IGC Pharma


Acquired the patent filings for IGC-AD1, a cannabis-based drug for treating Alzheimer’s from the University of South Florida. Development of IGC-AD1. 

IGC Pharma


Filed patents Tourette’s Syndrome, eating disorders, CNS disorders, fatigue and energy restoration. Launched Phase 1 safety and tolerability trial on IGC-AD1

IGC Pharma


Completed a Phase 1 clinical study on IGC-AD1 to evaluate safety and tolerability in participants with mild to moderate Alzheimer’s disease. Filed patents for compositions and methods for treating pain and for stress relief.

IGC Pharma


Acquired TGR-63, a molecule developed by the Jawaharlal Nehru Center for Advanced Scientific Research(JNCASR), which demonstrated, in Alzheimer’s cell lines, potential to reduce the plaque associated with Alzheimer’s.

Launched a Phase 2 double-blind, multi-site, clinical trial to evaluate the safety and efficacy of IGC-AD1 on agitation in dementia due to Alzheimer’s disease.